Thomas R. Fleming
Impact in
- Statistics and Probability top 0.01%
- Statistical Methods in Clinical Trials
- Statistical Methods and Inference
- Statistical Methods and Bayesian Inference
- Advanced Causal Inference Techniques
- Hepatology top 0.5%
- Liver Diseases and Immunity
Papers in
-
- Statistical Methods in Clinical Trials 58
- Statistical Methods and Inference 24
- Advanced Causal Inference Techniques 17
- Statistical Methods and Bayesian Inference 15
- Co-authors
- David P. Harrington (17 shared papers)Peter C. O’Brien (4 shared papers)Dorota M. Dabrowska (1 shared paper)Margaret S. Pepe (6 shared papers)Patricia M. Grambsch (5 shared papers)D. Y. Lin (4 shared papers)John H. Powers (4 shared papers)Lloyd D. Fisher (2 shared papers)
- Journals
- Clinical Trials (14 papers)Journal of Clinical Oncology (12 papers)Investigational New Drugs (11 papers)Statistics in Medicine (11 papers)Cancer (10 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Thomas R. Fleming
222 papers receiving 20.5k citations
Thomas R. Fleming's Hit Papers
Peers
Comparison fields: 5 of 208
- Statistics and Probability 5.6k
- Hepatology 1.6k
- Virology 807
- Statistics, Probability and Uncertainty 1.1k
- Infectious Diseases 2.2k
Countries citing papers authored by Thomas R. Fleming
This map shows the geographic impact of Thomas R. Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas R. Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas R. Fleming more than expected).
Fields of papers citing papers by Thomas R. Fleming
This network shows the impact of papers produced by Thomas R. Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas R. Fleming. The network helps show where Thomas R. Fleming may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas R. Fleming, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 226 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A Multiple Testing Procedure for Clinical Trials Hit paper breakdown → | 1979 | 2195 |
| 2 | Counting Processes and Survival Analysis. Hit paper breakdown → | 1992 | 1607 |
| 3 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial Hit paper breakdown → | 1999 | 1206 |
| 4 | Surrogate End Points in Clinical Trials: Are We Being Misled? Hit paper breakdown → | 1996 | 1094 |
| 5 | Targeted Anticytokine Therapy in Patients With Chronic Heart Failure Hit paper breakdown → | 2004 | 964 |
| 6 | A class of rank test procedures for censored survival data Hit paper breakdown → | 1982 | 840 |
| 7 | One-Sample Multiple Testing Procedure for Phase II Clinical Trials Hit paper breakdown → | 1982 | 832 |
| 8 | Prognosis in primary biliary cirrhosis: Model for decision making Hit paper breakdown → | 1989 | 624 |
| 9 | Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. Hit paper breakdown → | 1989 | 527 |
| 10 | Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis Hit paper breakdown → | 1989 | 481 |
| 11 | High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior Chemotherapy Hit paper breakdown → | 1985 | 451 |
| 12 | 1997 | 417 | |
| 13 | Biomarkers and surrogate endpoints in clinical trials Hit paper breakdown → | 2012 | 340 |
| 14 | Pediatric Pulmonary Hypertension Hit paper breakdown → | 2013 | 325 |
| 15 | 2001 | 304 | |
| 16 | 1995 | 280 | |
| 17 | 1995 | 279 | |
| 18 | 1984 | 241 | |
| 19 | SARS-CoV-2 Variants and Vaccines Hit paper breakdown → | 2021 | 226 |
| 20 | 1989 | 222 |
About Thomas R. Fleming
Thomas R. Fleming is a scholar working on Statistics and Probability, Pulmonary and Respiratory Medicine, Oncology, Economics and Econometrics and Infectious Diseases, having authored 226 papers that have together received 21.6k indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (58 papers), Health Systems, Economic Evaluations, Quality of Life (29 papers), Statistical Methods and Inference (24 papers), Meta-analysis and systematic reviews (20 papers), Advanced Causal Inference Techniques (17 papers), Statistical Methods and Bayesian Inference (15 papers), Colorectal Cancer Treatments and Studies (13 papers) and Ethics in Clinical Research (13 papers). The work is most often cited by research in Statistics and Probability (5.6k citations), Hepatology (1.6k citations), Virology (807 citations), Statistics, Probability and Uncertainty (1.1k citations) and Infectious Diseases (2.2k citations). Thomas R. Fleming has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include David P. Harrington, Peter C. O’Brien, Dorota M. Dabrowska, Margaret S. Pepe, Patricia M. Grambsch, D. Y. Lin, John H. Powers, Lloyd D. Fisher, Victor De Gruttola and Scott S. Emerson. Their work appears in journals such as Clinical Trials, Journal of Clinical Oncology, Investigational New Drugs, Statistics in Medicine and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.